MedTrace Logo

Phase II Study Evaluating the Clinical Efficacy and Safety of GN-037 in Plaque Psoriasis

NCT05706870 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 190

Last updated 2025-07-16

No results posted yet for this study

Summary

This Phase II study was designed as a multicenter, randomized, double-blind, placebo-controlled and 3-parallel arm, to assess clinical efficacy, safety, and tolerability of GN-037 versus clobetasol 17-propionate and placebo in patients diagnosed with mild to moderate plaque psoriasis at least 6 months ago

Conditions

Interventions

DRUG

GN-037

GN-037

DRUG

Clobetasol 17-propionate

Clobetasol 17-propionate

DRUG

Placebo

Placebo

Sponsors & Collaborators

  • Monitor CRO

    collaborator INDUSTRY

  • GEN İlaç ve Sağlık Ürünleri A.Ş.

    lead INDUSTRY

Principal Investigators

  • Nadir Ulu, MD PhD · Gen Ilac

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-12-07
Primary Completion
2024-01-04
Completion
2024-03-03

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05706870 on ClinicalTrials.gov